Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting GlobeNewswire - Fri Mar 7, 7:00AM CST

ARQT : 16.47 (-3.74%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Mar 5, 3:00PM CST

ARQT : 16.47 (-3.74%)
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting GlobeNewswire - Fri Feb 28, 8:00AM CST

ARQT : 16.47 (-3.74%)
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis  GlobeNewswire - Wed Feb 26, 7:00AM CST

ARQT : 16.47 (-3.74%)
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally Stocktwits - Wed Feb 26, 1:48AM CST

Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.

ARQT : 16.47 (-3.74%)
VTI : 281.16 (-1.17%)
IWM : 205.59 (-1.02%)
XBI : 85.08 (-2.30%)
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update GlobeNewswire - Tue Feb 25, 3:00PM CST

ARQT : 16.47 (-3.74%)
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology GlobeNewswire - Mon Feb 24, 7:00AM CST

ARQT : 16.47 (-3.74%)
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference GlobeNewswire - Tue Feb 18, 3:35PM CST

ARQT : 16.47 (-3.74%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Feb 5, 3:00PM CST

ARQT : 16.47 (-3.74%)
Arcutis to Present at the Guggenheim SMID Cap Biotech Conference GlobeNewswire - Mon Jan 27, 7:00AM CST

ARQT : 16.47 (-3.74%)

Barchart Exclusives

This Dividend Stock Yields 5.9%. Should You Buy It Now? Barchart - 44 minutes ago
Ford stock offers investors a balance of growth and income. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot